J&J Rybrevant/Lazcluze Combo Shows Big Survival Advantage In MARIPOSA Study

Topline Phase III results in EGFR exon 19 deletion/L858R substitution mutation NSCLC indicate more than a year in overall survival improvement over Tagrisso, the current standard of care.